EBITDA: Income before interest, taxes, depreciation and amortization.
Kymera Therapeutics, Inc. (KYMR) had EBITDA of $-349.96M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$39.21M |
|
$-311.35M |
|
-- |
|
$39.21M |
|
$388.61M |
|
$-349.40M |
|
$38.05M |
|
$-311.35M |
|
$-311.35M |
|
$-311.35M |
|
$-311.35M |
|
$-311.35M |
|
$-311.35M |
|
$-349.40M |
|
|
EBITDA |
$-349.96M |
84.49M |
|
84.49M |
|
$-3.69 |
|
$-3.69 |
|
| Balance Sheet Financials | |
$871.21M |
|
$43.17M |
|
$871.60M |
|
$1.74B |
|
$83.21M |
|
$1.46M |
|
$79.94M |
|
$163.15M |
|
$1.58B |
|
$1.58B |
|
$1.58B |
|
81.32M |
|
| Cash Flow Statement Financials | |
$-232.89M |
|
$-521.06M |
|
$990.71M |
|
$126.05M |
|
$362.81M |
|
$236.76M |
|
$59.90M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
10.47 |
|
-- |
|
-- |
|
0.00 |
|
0.00 |
|
100.00% |
|
-891.07% |
|
-891.07% |
|
-892.52% |
|
-794.04% |
|
-794.04% |
|
$-234.34M |
|
-- |
|
-- |
|
-- |
|
0.02 |
|
-- |
|
-- |
|
-- |
|
-19.71% |
|
-19.71% |
|
-17.86% |
|
-19.69% |
|
$19.42 |
|
$-2.77 |
|
$-2.76 |
|